GlobeNewswire: WPD Pharmaceuticals Contains the last 10 of 74 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:17:32ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/05/16/2443747/0/en/WPD-Pharmaceuticals-Signs-Annex-to-License-Agreement-with-Wake-Forest-University-Health-Sciences.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health Sciences2022-05-16T11:30:00Z<![CDATA[VANCOUVER, British Columbia, May 16, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is excited to announce that it has signed Annex No. 2 into its License Agreement with Wake Forest University Health Sciences (“WFUHS”). On April 22, 2022 WPD Pharmaceuticals Sp. z o.o. (“WPD Poland”), the Polish subsidiary of the Company, signed Annex No 2. into the License Agreement. Previous to Annex No. 2, WPD signed Annex No. 1 to the License Agreement on June 30, 2019. The original License Agreement with WFUHS has been in place since November 28, 2017, and both WPD and WFUHS have worked collaboratively since then.]]>https://www.globenewswire.com/news-release/2022/03/07/2397832/0/en/WPD-Pharmaceuticals-Signs-Consortium-Agreement-on-EuroNanoMed-Project.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed Project2022-03-07T12:30:00Z<![CDATA[Expert research team aiming to optimize the effects of radiotherapy of brain tumors Expert research team aiming to optimize the effects of radiotherapy of brain tumors]]>https://www.globenewswire.com/news-release/2022/02/09/2381753/0/en/WPD-Pharmaceuticals-Announces-Proposed-Restructuring-of-Polish-Subsidiary.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Announces Proposed Restructuring of Polish Subsidiary2022-02-09T12:30:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1) announces that the Company’s board of directors (the “Board”) has approved a plan to restructure (the “Restructuring”) the outstanding capitalization of the Company’s wholly owned Polish subsidiary WPD Pharmaceuticals sp. z.o.o. (“WPD Poland”). Due to the occurrence of negative shareholders’ equity in WPD Poland, under Polish corporate law, WPD Poland is obligated to convene an extraordinary general meeting of its shareholders to vote on the implementation of a recovery plan or file a bankruptcy proceeding. As the Company is sole shareholder of WPD, the Board has approved a recovery plan of WPD Poland, being the Restructuring. Under the Restructuring, the first step is that the outstanding share capital of WPD Poland will be reduced through a voluntary redemption of 53,384 shares of WPD Poland by the Company for no cash consideration, which will increase the supplementary and reserve capitals of WPD Poland. Under the second step, the share capital of WPD Poland will be increased due to the conversion of loan receivables due to the Company into new shares of WPD Poland. The Company believes that the Restructuring will enable WPD Poland to operate and pursue its research and development objectives. The Company will provide more updates as the Restructuring plan is implemented.]]>https://www.globenewswire.com/news-release/2022/02/03/2378391/0/en/WPD-Pharmaceuticals-Announces-Appointment-of-New-Director.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Announces Appointment of New Director2022-02-03T12:30:00Z<![CDATA[VANCOUVER, British Columbia, Feb. 03, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that the Company appointed Mr. Romuald Harwas as a director of the Company, effective February 2, 2022. The appointment of Mr. Harwas filled the vacancy created by the prior resignation of Walter Klemp on October 14, 2021.]]>https://www.globenewswire.com/news-release/2022/02/01/2376576/0/en/WPD-Pharmaceuticals-Secures-Berubicin-Sub-License-Rights-in-Perpetuity.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Secures Berubicin Sub-License Rights in Perpetuity2022-02-01T12:30:00Z<![CDATA[Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during the applicable development period Commercially Reasonable Development Expenditures of at least US$2,000,000 going towards the development, testing, regulatory approval or commercialization of the licensed product, Berubicin, during the applicable development period]]>https://www.globenewswire.com/news-release/2022/01/25/2372405/0/en/WPD-Pharmaceuticals-Enters-into-Amended-and-Restated-Sublicense-Agreement-with-Moleculin-Biotech.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin Biotech2022-01-25T12:30:00Z<![CDATA[VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (the “Company” or “WPD”) (CSE: WBIO) (FSE: 8SV1), is pleased to announce that it has entered into an amended and restated sublicense agreement (the “Sublicense Agreement”) with Moleculin Biotech Inc. (“Moleculin”). On December 20, 2021, WPD Pharmaceuticals Sp. z o.o. (“WPD Poland”), the Polish subsidiary of the Company, entered into an amendment of its February 2019 sublicense (as amended previously in 2019 and 2021) from Moleculin of certain intellectual property rights, including certain rights to Moleculin’s Annamycin, WP1066 and WP1122 portfolios to research, develop, manufacture, use, import, offer and sell products derived from these portfolios in the field of human therapeutics (“Products”) in 29 countries, including some countries in Europe (the “Territories”).]]>https://www.globenewswire.com/news-release/2021/12/16/2353512/0/en/WPD-Pharmaceuticals-Signs-Agreement-with-NCRD-for-6-3M-Grant-for-the-Development-of-Liposomal-Annamycin-Intended-as-a-Treatment-for-AML.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Signs Agreement with NCRD for $6.3M Grant for the Development of Liposomal Annamycin, Intended as a Treatment for AML2021-12-16T12:30:00Z<![CDATA[VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that it was informed that the Polish National Center for Research and Development (“NCRD”) has signed an agreement with WPD for a grant of C$6.3 million (20,394,049.68 PLN) for the development of Liposomal Annamycin for the treatment of Acute Myeloid Leukemia.]]>https://www.globenewswire.com/news-release/2021/10/01/2306940/0/en/WPD-Pharmaceuticals-Announces-AGSM-Results.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Announces AGSM Results2021-10-01T11:30:00Z<![CDATA[VANCOUVER, British Columbia, Oct. 01, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces the results of its annual general and special meeting held September 29, 2021 in Vancouver, Canada.]]>https://www.globenewswire.com/news-release/2021/09/02/2290772/0/en/WPD-Pharmaceuticals-Announces-AGM-September-29-Plans-Different-Path-to-Fundraising-Through-Delisting-WPD-Poland-Arranges-Additional-Loans-Communications-Consultant-in-Poland.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals Announces AGM September 29; Plans Different Path to Fundraising Through Delisting; WPD Poland Arranges Additional Loans; Communications Consultant in Poland2021-09-02T11:30:00Z<![CDATA[VANCOUVER, British Columbia, Sept. 02, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, announces that it will hold its Annual and Special General Meeting of Shareholders (AGSM) on September 29, 2021 in Vancouver, Canada at 10 AM. The AGSM Notice of Meeting and Management Information Circular will be filed on SEDAR and will shortly be mailed to shareholders. In light of continued COVID restrictions, shareholders are encouraged to vote their shares online and attend the meeting through Zoom.]]>https://www.globenewswire.com/news-release/2021/07/12/2261091/0/en/WPD-Pharmaceuticals-Licensor-Receives-FDA-Fast-Track-Designation-for-Berubicin-for-the-Treatment-of-Recurrent-Glioblastoma-Multiforme-WPD-Poland-Arranges-Loans.html?f=22&fvtc=4&fvtv=58008WPD Pharmaceuticals’ Licensor Receives FDA Fast Track Designation for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme; WPD Poland Arranges Loans2021-07-12T11:30:00Z<![CDATA[VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical company, is pleased to announce that CNS Pharmaceuticals Inc. (“CNS”) (NASDAQ:CNSP), the company that licenses the drug candidate Berubicin to WPD for 29 countries mainly in Europe, announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme (GBM). As previously reported, CNS had also received Orphan Drug Designation from the FDA for Berubicin for the treatment of patients with recurrent GBM.]]>